8247 Stock Overview
Manufactures, sells, and distributes in-vitro diagnostic reagents in Mainland China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Biosino Bio-Technology and Science Incorporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.80 |
| 52 Week High | HK$1.38 |
| 52 Week Low | HK$0.48 |
| Beta | -0.32 |
| 11 Month Change | 17.65% |
| 3 Month Change | 23.08% |
| 1 Year Change | -20.00% |
| 33 Year Change | -55.06% |
| 5 Year Change | -44.83% |
| Change since IPO | -70.64% |
Recent News & Updates
Biosino Bio-Technology and Science Incorporation's (HKG:8247) Business And Shares Still Trailing The Industry
Oct 31
Biosino Bio-Technology and Science Incorporation's (HKG:8247) 26% Dip In Price Shows Sentiment Is Matching Revenues
Jun 27Shareholders Will Probably Be Cautious Of Increasing Biosino Bio-Technology and Science Incorporation's (HKG:8247) CEO Compensation At The Moment
Jun 21Recent updates
Biosino Bio-Technology and Science Incorporation's (HKG:8247) Business And Shares Still Trailing The Industry
Oct 31Biosino Bio-Technology and Science Incorporation's (HKG:8247) 26% Dip In Price Shows Sentiment Is Matching Revenues
Jun 27Shareholders Will Probably Be Cautious Of Increasing Biosino Bio-Technology and Science Incorporation's (HKG:8247) CEO Compensation At The Moment
Jun 21Biosino Bio-Technology and Science Incorporation (HKG:8247) Held Back By Insufficient Growth Even After Shares Climb 46%
Apr 22Is Biosino Bio-Technology and Science Incorporation (HKG:8247) Using Debt In A Risky Way?
Apr 01Biosino Bio-Technology and Science Incorporation's (HKG:8247) 31% Dip In Price Shows Sentiment Is Matching Revenues
Feb 08Some Confidence Is Lacking In Biosino Bio-Technology and Science Incorporation (HKG:8247) As Shares Slide 38%
Jul 31Shareholder Returns
| 8247 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -12.1% | -4.8% | -5.3% |
| 1Y | -20.0% | -14.6% | 11.3% |
Return vs Industry: 8247 underperformed the Hong Kong Biotechs industry which returned -14.6% over the past year.
Return vs Market: 8247 underperformed the Hong Kong Market which returned 11.3% over the past year.
Price Volatility
| 8247 volatility | |
|---|---|
| 8247 Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in HK Market | 19.1% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 8247 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 8247's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 554 | Peng Chen | www.sinobio.com.cn |
Biosino Bio-Technology and Science Incorporation, together with its subsidiaries, manufactures, sells, and distributes in-vitro diagnostic reagents in Mainland China. It offers clinical chemistry reagents, including single and double reagents, calibrators, QC products, and washing solution detergents; Elisa kits; rapid tests; and analyzers. The company also provides medical and medical inspection services; produces and sells medical instruments; and researches and develops, sells, and distributes biological reagents and instruments.
Biosino Bio-Technology and Science Incorporation Fundamentals Summary
| 8247 fundamental statistics | |
|---|---|
| Market cap | HK$115.77m |
| Earnings (TTM) | -HK$20.90m |
| Revenue (TTM) | HK$305.58m |
0.4x
P/S Ratio-5.5x
P/E RatioIs 8247 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8247 income statement (TTM) | |
|---|---|
| Revenue | CN¥283.76m |
| Cost of Revenue | CN¥164.54m |
| Gross Profit | CN¥119.22m |
| Other Expenses | CN¥138.63m |
| Earnings | -CN¥19.41m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 42.02% |
| Net Profit Margin | -6.84% |
| Debt/Equity Ratio | 66.3% |
How did 8247 perform over the long term?
See historical performance and comparison